A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18INK4C Expression in Advanced Breast Carcinoma.

doi:10.1016/j.modpat.2025.100841

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18INK4C Expression in Advanced Breast Carcinoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Dec 2025

Huang Xiao, Varambally Sooryanarayana, Anderson Sarah A, Bartow Brooke B, Harada Shuko, Wei Shi, Siegal Gene P, Khoury Katia, Yalniz Ceren

Abstract excerpt

Cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) with endocrine therapy benefits patients with hormone receptor-positive, human epidermal growth receptor 2-negative breast carcinomas. However, most tumors develop resistance to CDK4/6i during the course of therapy. Although preclinical studies have proposed molecular mechanisms for the resistance, predictive markers are yet to be discovered. We investigated the...

Read the complete abstract on PubMed

Topics

Humans
GATA3 Transcription Factor
Female
Breast Neoplasms
Cyclin-Dependent Kinase 4

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Middle Aged

Cyclin-Dependent Kinase 6

Cyclin-Dependent Kinase Inhibitor p18

Aged

Protein Kinase Inhibitors

Adult

Biomarkers, Tumor

Mutation

Drug Resistance, Neoplasm

Source

Open in PubMed

Identifiers

PMID: 40680849
DOI: 10.1016/j.modpat.2025.100841

Genes

CDK4
GATA3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 27 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18INK4C Expression in Advanced Breast Carcinoma.PMID 40680849Read ↗

GATA3 somatic mutations are associated with clinicopathological features and expression profile in TCGA breast cancer patients.Semantic proximity Read ↗

The Significance and Therapeutic Potential of GATA3 Expression and Mutation in Breast Cancer: A Systematic Review.Semantic proximity Read ↗

Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer TherapySemantic proximity Read ↗

LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 proteinSemantic proximity Read ↗

Potential role of significant GATA3 mutation in male breast cancer responding to endocrine therapy: A case report.Semantic proximity Read ↗

GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.Semantic proximity Read ↗

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase InhibitorsSemantic proximity Read ↗

Mutation of GATA3 in human breast tumors.Semantic proximity Read ↗

Comprehensive analysis of the GATA transcription factor gene family in breast carcinoma using gene microarrays, online databases and integrated bioinformaticsSemantic proximity Read ↗

GATA3frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primaryGATA3mutant breast cancersSemantic proximity Read ↗

Loss of function of GATA3 induces basal-like mammary tumorsSemantic proximity Read ↗

Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.